Last reviewed 2026-04-22 · How we verify

Colaren in HIV positive

University of Guadalajara · Phase 3 active Small molecule

Colaren in HIV positive is a Small molecule drug developed by University of Guadalajara. It is currently in Phase 3 development for HIV infection in antiretroviral-treated patients. Also known as: plus Zoledronic Acid 4 mg.

Colaren is an immunomodulatory agent designed to enhance immune function and reduce viral replication in HIV-positive patients.

Colaren is an immunomodulatory agent designed to enhance immune function and reduce viral replication in HIV-positive patients. Used for HIV infection in antiretroviral-treated patients.

At a glance

Generic name	Colaren in HIV positive
Also known as	plus Zoledronic Acid 4 mg
Sponsor	University of Guadalajara
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

While specific mechanistic details are limited in public literature, Colaren appears to work by modulating immune responses to improve CD4+ T cell function and control HIV viral load. The drug is being investigated as a potential therapeutic agent to support antiretroviral therapy in HIV management.

Approved indications

HIV infection in antiretroviral-treated patients

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Colaren in HIV positive CI brief — competitive landscape report
Colaren in HIV positive updates RSS · CI watch RSS
University of Guadalajara portfolio CI

Frequently asked questions about Colaren in HIV positive

What is Colaren in HIV positive?

Colaren in HIV positive is a Small molecule drug developed by University of Guadalajara, indicated for HIV infection in antiretroviral-treated patients.

How does Colaren in HIV positive work?

Colaren is an immunomodulatory agent designed to enhance immune function and reduce viral replication in HIV-positive patients.

What is Colaren in HIV positive used for?

Colaren in HIV positive is indicated for HIV infection in antiretroviral-treated patients.

Who makes Colaren in HIV positive?

Colaren in HIV positive is developed by University of Guadalajara (see full University of Guadalajara pipeline at /company/university-of-guadalajara).

Is Colaren in HIV positive also known as anything else?

Colaren in HIV positive is also known as plus Zoledronic Acid 4 mg.

What development phase is Colaren in HIV positive in?

Colaren in HIV positive is in Phase 3.

Manufacturer: University of Guadalajara — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for HIV infection in antiretroviral-treated patients
Also known as: plus Zoledronic Acid 4 mg
Compare: Colaren in HIV positive vs similar drugs
Pricing: Colaren in HIV positive cost, discount & access